Evidence map›Paper›PMID 31740662›Full record

ArticleTranslational psychiatry2019

Integrative proteomics and pharmacogenomics analysis of methylphenidate treatment response.

Bruna S da Silva, Douglas T Leffa, Walter O Beys-da-Silva, Iraci L S Torres, Diego L Rovaris, Marcelo M Victor, Luis A Rohde, Nina R Mota, Carla de Oliveira, Markus Berger and 8 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Effects of Methylphenidate on the Dopamine Transporter and Beyond.Current topics in behavioral neurosciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Bruna S da SilvaDepartment of Genetics, Institute of Biosciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Douglas T LeffaPostgraduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Walter O Beys-da-SilvaFaculty of Pharmacy, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID http://orcid.org/0000-0001-8329-7839
Iraci L S TorresPostgraduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID http://orcid.org/0000-0002-3081-115X
Diego L RovarisDepartment of Genetics, Institute of Biosciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Marcelo M VictorADHD Outpatient Program, Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Luis A RohdeADHD Outpatient Program, Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Nina R MotaDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-3504-759X
Carla de OliveiraPostgraduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Markus BergerCenter of Experimental Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
John R YatesDepartment of Chemical Physiology, Scripps Research, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-5267-1672
Renuka SabnisProteomics Facility, Sanford-Burnham-Prebys Medical Discovery Institute, 10901N. Torrey Pines Road, La Jolla, CA, 92037, USA.
Ramón Díaz PeñaProteomics Facility, Sanford-Burnham-Prebys Medical Discovery Institute, 10901N. Torrey Pines Road, La Jolla, CA, 92037, USA.
Alexandre Rosa CamposProteomics Facility, Sanford-Burnham-Prebys Medical Discovery Institute, 10901N. Torrey Pines Road, La Jolla, CA, 92037, USA.
Eugenio H GrevetADHD Outpatient Program, Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Lucelia SantiFaculty of Pharmacy, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID http://orcid.org/0000-0002-5698-7006
Claiton H D BauDepartment of Genetics, Institute of Biosciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. claiton.bau@ufrgs.br.
Verônica ContiniADHD Outpatient Program, Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Universidade Federal do Rio Grande do Sul · BRSanford Burnham Prebys Medical Discovery Institute · USHospital de Clínicas de Porto Alegre · BRRadboud University Nijmegen · NLScripps Institution of Oceanography · USUnivates · BR

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI YATES III, JOHN R · 2012 to 2021
$20.7M
Quantitative Proteome Analysis of Brain DevelopmentR01MH067880 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI YATES III, JOHN R · 2003 to 2017
$7.1M
NCI NIH HHS P30 CA030199NIGMS NIH HHS P41 GM103533NIMH NIH HHS R01 MH067880
6 · The paper itself

Abstract

Transcriptomics and candidate gene/protein expression studies have indicated several biological processes modulated by methylphenidate (MPH), widely used in attention-deficit/hyperactivity disorder (ADHD) treatment. However, the lack of a differential proteomic profiling of MPH treatment limits the understanding of the most relevant mechanisms by which MPH exerts its pharmacological effects at the molecular level. Therefore, our aim is to investigate the MPH-induced proteomic alterations using an experimental design integrated with a pharmacogenomic analysis in a translational perspective. Proteomic analysis was performed using the cortices of Wistar-Kyoto rats, which were treated by gavage with MPH (2 mg/kg) or saline for two weeks (n = 6/group). After functional enrichment analysis of the differentially expressed proteins (DEP) in rats, the significant biological pathways were tested for association with MPH response in adults with ADHD (n = 189) using genome-wide data. Following MPH treatment in rats, 98 DEPs were found (P < 0.05 and FC < -1.0 or > 1.0). The functional enrichment analysis of the DEPs revealed 18 significant biological pathways (gene-sets) modulated by MPH, including some with recognized biological plausibility, such as those related to synaptic transmission. The pharmacogenomic analysis in the clinical sample evaluating these pathways revealed nominal associations for gene-sets related to neurotransmitter release and GABA transmission. Our results, which integrate proteomics and pharmacogenomics, revealed putative molecular effects of MPH on several biological processes, including oxidative stress, cellular respiration, and metabolism, and extended the results involving synaptic transmission pathways to a clinical sample. These findings shed light on the molecular signatures of MPH effects and possible biological sources of treatment response variability.

Indexed as

AdultAnimalsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsFemaleHumansMaleMethylphenidatePharmacogeneticsProteomicsRandom AllocationRatsRats, Inbred WKYCentral Nervous System StimulantsMethylphenidate

Identifiers

PMID31740662
PMCPMC6861257
OpenAlexW2985827412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.